title: Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma.
abstract: Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.
authors.affiliation: Division of Medical Oncology A, Aviano Cancer Institute, Aviano, PN, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Vaccher
authors.forename: Giampiero
authors.initials: G
authors.lastname: di Gennaro
authors.forename: Cecilia
authors.initials: C
authors.lastname: Simonelli
authors.forename: Ornella
authors.initials: O
authors.lastname: Schioppa
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin